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Abstract
Rationale: Intravascular large B-cell lymphoma (IVLBCL) is a type of malignant lymphoma in which neoplastic B cells proliferate
selectively within the lumina of small- andmedium-sized vessels. Patients with IVLBCL frequently develop neurological manifestations
during their disease course. Patients are known to often develop various neurological manifestations, but there are only a few reports
of IVLBCL whose initial symptoms are deafness and/or disequilibrium.
Patient concerns: A 66-year-old Japanese man was provisionally diagnosed with sudden sensorineural hearing loss.
Administration of prednisolone did not improve his symptoms, and then he experienced amaurosis fugax. Magnetic resonance
imaging (MRI) showed multiple brain infarcts, so he was administered antithrombotic drugs. Nevertheless, he experienced recurrent
strokes, became irritable, and had visual hallucinations. He was emergently admitted to our hospital with disturbance of
consciousness.
Diagnosis: Blood tests showed elevation of lactose dehydrogenase and soluble interleukin-2 receptor. Cranial MR diffusion-
weighted imaging showed multiple lesions bilaterally in the cerebral white matter and cortex, posterior limbs of the internal capsule,
and cerebellar hemispheres, which were hypointense on apparent diffusion coefﬁcient maps. Hyperintense lesions were detected
bilaterally in the cerebral white matter and basal ganglia on both T2-weighted imaging and ﬂuid-attenuated inversion recovery
imaging. Contrast-enhanced brain MRI demonstrated contrast-enhancing high-signal lesions along the cerebral cortex. Brain biopsy
revealed a diagnosis of IVLBCL.
Interventions: The patient could not receive chemotherapy because of his poor general condition. Therefore, we administered
high-dose methylprednisolone (mPSL) pulse therapy.
Outcomes:There was little improvement in consciousness levels after the high-dosemPSL pulse therapy. On the forty-ninth day of
hospitalization, he was transferred to another hospital to receive supportive care.
Lessons: IVLBCL should be regarded as an important differential diagnosis of hearing loss and dizziness. Most importantly, if the
symptoms are ﬂuctuant and steroid therapy is not effective, biopsy should be considered as early as possible.
Abbreviations: CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, DWI = diffusion-weighted imaging,
IVLBCL = intravascular large B-cell lymphoma, MRI = magnetic resonance imaging, s-IL2R = soluble interleukin-2 receptor.
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11. Introduction
Intravascular large B-cell lymphoma (IVLBCL) is a type of
malignant lymphoma in which neoplastic B cells proliferate
selectively within the lumina of small- and medium-sized vessels,
without the involvement of adjacent parenchymal tissue.[1] The
incidence of IVLBCL is estimated to be less than 1 person per
million.[2] The disease occurs slightly more frequently inmen, and
most often in the advanced age.[2] IVLBCL usually presents with
central nervous system and dermatological lesions in Western
countries or with hemophagocytic syndrome in Asian countries,
mainly in Japan.[1] Since the progression of the disease is
aggressive and rapid, and the prognosis is lethal when the
diagnosis and therapy are delayed, early diagnosis is crucial;
however, there is not good blood- or CSF-biomarker, and the
appearance of MRI ﬁndings is not speciﬁc. Raising IVLBCL as a
differential diagnosis is critically important against nonspeciﬁc
symptoms. Patients frequently develop neurological manifesta-
tions during their disease course, such as encephalopathy, seizure,
[3]
Figure 1. Diffusion-weighted magnetic resonance (MR) images on the admission day (A–C) and on the thirteenth day (D–E) of hospitalization. (A) Diffusion-weighted
images, showing multiple high-intensity lesions in bilateral cerebral white matter and cortex, posterior limbs of the internal capsule, and cerebellar hemispheres. (B)
Apparent diffusion coefﬁcientmaps. (C) T2-weightedMR images demonstratingmultiple high-intensity areas in bilateral cerebral whitematter and basal ganglia. (D and E)
Gadolinium-enhanced T1-weighted MR images on the thirteenth day of hospitalization showing contrast-enhancing high-signal areas along the cortex in regions of the
right frontal lobe (openarrow inD),bilateral parietal lobe,and leftparieto-occipital region (arrows inD). The lesionat the right frontal lobe ismagniﬁedanddemonstrated in (E).
Miyake et al. Medicine (2019) 98:7 Medicinemyelopathy, radiculopathy, or neuropathy. However, there are
only a few reports of IVLBCL whose initial symptoms are
deafness and/or disequilibrium. Here, we report on a patient with
IVLBCL presenting with hearing loss and dizziness.2. Case presentation
A66-year-old Japaneseman developed hearing loss in the left ear.
Five months later, he felt his ear blocked, and he realized tinnitus2and dizziness. He consulted an otolaryngologist and was
diagnosed with peripheral vertigo. Betahistine mesilate was
administered for his symptoms, but no improvement was
observed. He consulted another otolaryngologist and was
tentatively diagnosed with sudden sensorineural hearing loss.
Ten days of intravenous prednisolone partially improved his
dizziness, but hearing loss and tinnitus continued. About two
months later, he showed transient visual obscuration in the right
side, so he saw a neurosurgeon who emergently performed brain
Figure 2. Histopathology of the biopsy brain specimen. (A) Hematoxylin and eosin staining showing intravascular proliferation of neoplastic lymphoid cells (arrows).
(B) CD20 and (C) CD79a staining. Original magniﬁcations: A, 200; B and C, 100.
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amaurosis fugax and cardiac embolisms and was started on
apixaban. One month later, his hearing loss in both ears and
dizziness worsened. Administration of prednisolone did not
relieve his symptoms, and he could not walk without a walker. In
brain MRIs, there were several new cerebral infarcts. He became
irritated, started to talk and behave illogically, and had visual
hallucinations. He repeatedly fell down and could not hold onto
anything. One year after the emergence of the initial symptoms,
he was admitted to our hospital because of disturbance of
consciousness.
His past medical history included treated hypertension and
hyperuricemia. Our physical examination revealed a body
temperature of 37.3°C, blood pressure of 118/93mm Hg, pulse
rate of 108/min, respiration rate of 19/min, and peripheral
oxygen saturation of 100% with a 3L/min oxygen mask. His
conscious level on arrival was E1V1M5 on the Glasgow Coma
Scale. General physical examination results were normal;
however, neurological examination revealed a positive doll’s
eye phenomenon, muscle weakness in the lower extremities, and
exaggerated tendon reﬂexes in all four extremities. No neck
stiffness was found, and otoacoustic emissions were compatible
with both sensorineural hearing loss. The number of white blood
cells was 10,100/mL, andC-reactive proteinwas 5.59mg/dL. The
patient’s blood urea nitrogen was 47.0mg/dL, creatinine 1.81
mg/dL, aspartate aminotransferase 41 IU/L, lactase dehydroge-
nase 267 IU/L, ﬁbrinogen 619.6mg/dL, and D-dimer 2.0mg/mL.
Serum-soluble interleukin-2 receptor (s-IL2R) was 1290U/mL,
whereas carcinoembryonic antigen (CEA), carbohydrate antigen
19-9 (CA19-9), and prostate-speciﬁc antigen were not elevated.
Serum lactic acid and pyruvic acidwerewithin normal limits. The
patient’s thyroid function was normal, and antinuclear, anti-
Sjögren’s-syndrome (SS)-related antigen A, anti-SSB, proteinase
3-anti-neutrophil cytoplasmic, and myeloperoxidase-anti-neu-
trophil cytoplasmic antibodies were not detected. Syphilis,
hepatitis, and HIV serologies were negative. Cerebrospinal ﬂuid
analysis showed the following: opening pressure of 160mm
H2O, 3cells/mL (90% mononuclear, 10% polymorphonuclear),
total protein of 85mg/dL, glucose 71mg/dL (124mg/dL in the
serum), CEA <0.2ng/mL, CA19-9 <0.6U/mL, angiotensin
converting enzyme <1.0U/mL, s-IL2R 60U/mL, beta 2-micro-3globulin 3.3mg/L; neither cytology nor comprehensive microbi-
ological studies showed positive results. Holter
electrocardiogram showed no atrial ﬁbrillation, and there were
no abnormalities in chest X-ray and transthoracic cardiac
ultrasonography. Contrast-enhanced computed tomography
showed no malignancies. Cranial MRI revealed hyperintense
bilateral lesions in the cerebral white matter and cortex,
suggesting multiple watershed infarctions, while diffusion-
weighted imaging (DWI) showed lesions in the posterior limbs
of the internal capsule and cerebellar hemispheres (Fig. 1A).
Reduction in signals at those lesions was seen on apparent
diffusion coefﬁcient maps (Fig. 1B). There were multiple
hyperintense lesions bilaterally in the cerebral white matter
and basal ganglia on both T2-weighted (Fig. 1C) and ﬂuid-
attenuated inversion recovery imaging (not shown). Magnetic
resonance angiography results were normal. Contrast-enhanced
brain MRI, performed on the thirteenth day of hospitalization,
revealed contrast-enhancing high-signal lesions along the cortex
at the level of the right frontal lobe, which were hyperintense on
DWI, as well as bilaterally in the parietal lobe and in the left
parieto-occipital region (Fig. 1D and E; arrows and open
arrows).
Based on the patient’s clinical course, laboratory data, and
neuroimaging results, we suspected intravascular lymphoma;
however, skin biopsy did not conﬁrm this diagnosis. On the
twenty-eighth day of hospitalization, we performed cerebral
biopsy of the right frontal lesion. Histopathological examination
revealed proliferation of large atypical lymphoid cells in the
vessels (Fig. 2A; arrows). Immunohistochemical analysis showed
that the neoplastic cells were positive for CD20 (Fig. 2B) and
CD79a (Fig. 2C) antigens, B-cell lymphoma 6, multiple
myeloma-1, and Ki67 (not shown), thus leading to a diagnosis
of IVLBCL.
We administered high-dose methylprednisolone pulse therapy
(1g/day, for 3 days), but little improvement of consciousness
disturbance was observed. We consulted the department of
hematology considering the possibility of chemotherapy, but this
was not indicated because of the patient’s poor general status. On
the forty-ninth day of hospitalization, he was transferred to
another hospital to receive the best supportive care. Three days
later, he died. The summary is shown in the Table 1.
Table 1
Demographic and clinical characteristics of previously reported cases and ours.
Yamaoka (2010)[6] Kanazawa (2014)[7] Aoyama (2003)[8] Mitsutake (2015)[9] Berger (2005)[10] Our case
Age (years) 66 60 54 66 61 66
Sex Female Male Male Female Male Male
Initial symptoms Hearing loss Vertigo, headache Hearing loss Vertigo, hearing loss Vertigo, hearing loss, nausea Dizziness, hearing loss
Rashes + + – – – –
LDH (U/L) 1095 243 552 782 Unknown 267
s-IL2R (U/mL) 3040 1660 1090 1396 Unknown 1290
Cerebrospinal ﬂuid
Cells (/mL) 2 9 2 Normal 12 3
Protein (mg/dL) 24 138 39 Normal 217 85
Multiple infarctions + + + + + +
Infratentorial lesions Pons – – Cerebellum Pons Medulla Cerebellum
Biopsy Brain Kidney Brain Brain, skin Brain Brain
Therapy/outcomes R-CHOP/Remission R-CHOP/Remission R-CHOP/Death R-CHOP/Remission Anticoagulation/Death None/Death
LDH= lactase dehydrogenase, s-IL2R= soluble interleukin-2 receptor.
Miyake et al. Medicine (2019) 98:7 MedicineThe ethical approval was not necessary because this was a case
report. The patient’s family provided informed consent for the
publication of his clinical data.3. Discussion
We report the case of a patient with initial symptoms of recurrent
hearing loss and dizziness, who developed multiple strokes of
unknown origin and required brain biopsy to establish a
diagnosis of IVLBCL. Our case resembles that reported in
Western countries as the patient did not show cutaneous lesions.
Glass et al. reported that over 60% of patients with IVLBCL
develop neurological symptoms during their disease course; 76%
develop progressive and multifocal cerebrovascular disorder;
38%myelopathy and radiculopathy; 27% subacute encephalop-
athy; 21% cranial nerve dysfunction; and 5% develop neuropa-
thy.[2] Unfortunately, none of these symptoms is speciﬁc to
IVLBCL, thus making diagnosis laborious. R-CHOP chemother-
apy, which employs rituximab, cyclophosphamide, hydroxy-
daunomycin, vincristine, and prednisolone, can extend life
prognosis[1]; therefore, it is essential to diagnose the disease
properly in the early stage and distinguish it from cerebral
infarction. Tissue biopsy is necessary to diagnose IVLBCL; skin,
bone marrow, muscles, peripheral nerves, and brain should be
selected for the biopsy. In particular, skin biopsy should be
considered ﬁrst, since it is less invasive than biopsy of other
tissues. Nonetheless, many past cases required brain biopsy for
the diagnosis of IVLBCL.[4]
Our case was not typical of the disease since the bilateral
symptoms ﬂuctuated and he experienced repeated dizzy spells.
Only 1.7% of cases of sudden sensorineural hearing loss are
reported to show bilateral symptoms,[5] which usually do not
ﬂuctuate. As shown in the Table 1, some studies have also
reported patients with deafness, dizziness, or both as the initial
symptoms.[6–10] Hearing loss was found bilaterally in 3 patients
and even unilaterally in 2 patients. In all cases, including ours,
multiple lesions were found in the supratentorial region. In some
cases, lesions were observed in the brain stem or cerebellum by
MRI, but in others, like in our case, no such lesions were found.
We propose that the sudden deafness in our patient was caused by
infarction of the proper cochlear artery, and that dizziness was
caused by the propagation of the occlusion proximally to the level
of the labyrinthine artery or the anterior inferior cerebellar artery,4although it is difﬁcult to prove this by imaging studies. In 3
patients, brain biopsywas necessary for diagnosis (Table 1).[6,8,10]
In contrast, remission was achieved with R-CHOP therapy in 3
cases, and 2 patients died during the course of the chemothera-
py.[8,10] In our case, however, when the diagnosis of IVLBCL was
conﬁrmed, the patient could not receive R-CHOP therapy
because of his poor condition.4. Conclusion
IVLBCL is a rare but critical cause for hearing loss and dizziness
and should be considered as a diagnosis, particularly when the
clinical course of the patient is not typical for sudden
sensorineural hearing loss and when recurrent strokes occur.
Our report highlights the diagnostic role of cerebral biopsy, since
skin biopsy, although less invasive, does not always lead to
correct diagnosis. Prevalence of IVLBCL among the patients
presenting a deafness and dizziness should be clariﬁed.Acknowledgments
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